Andrew Walsh Joins Annovis Bio as VP of Finance Amid Pivotal Clinical Trials

Annovis Bio

BERWYN, PA — In a recent announcement, Berwyn, Pennsylvania-based clinical-stage drug platform company Annovis Bio, Inc. (NYSE: ANVS) has appointed Andrew Walsh as its new Vice President of Finance. This appointment comes at a critical time for the company as it prepares to receive crucial data from its Alzheimer’s and Parkinson’s clinical trials in 2024.

Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, expressed her enthusiasm about the addition of Walsh to the team, stating that his appointment is another step in their growth plans. “Andrew brings 12 years of extensive experience in finance operations, adding a significant layer of strength that will be integral to the company’s continued success,” she said.

Walsh, equally excited about his new role, looks forward to working with Maria and the leadership team to help advance Annovis during this pivotal time. He emphasized on working collaboratively to position the Company to achieve its goals.

Prior to joining Annovis, Walsh served as the Senior Director, Finance and Treasury at Ocugen, a clinical stage biotechnology company known for developing innovative gene and cell therapies as well as vaccines. His career began at KPMG in corporate tax, followed by roles of increasing responsibility at InVentiv Health, PQ Corporation, and Potters Industries. Walsh is a summa cum laude graduate in Accounting from Drexel.

With Walsh’s solid financial operations experience, his appointment is a key strategic move in Annovis Bio’s growth trajectory. His skills are expected to be vital to the company’s future successes, especially as the company gears up for its fundamental clinical trials in 2024.

READ:  Envestnet's Revenue Manager Revolutionizes Billing for Intech Investment Management

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.